New Threats
Countering Bioterrorism: Prevention and Protection
14:30 - 15:45
Transportation: Keeping bioterrorism agents out of circulation

Preventing terrorists from procuring and developing biological weapons is the most cost-effective way to counter bio-terrorism. But with the lack of bio-security at some facilities and laboratories, the threat of biological agents being diverted must remain a seious concern. Preventing the diversion and transportation of select agents requires close inter-state coordination and collaboration. At the same time, what can the EU do to strenghten its dual-use export regime? And  can the wider use of advanced technologies help reduce the risk of diversion and the illicit transportation of agents?

Barry Kellman, Director, International Weapons Control Center and Co-Chair of Session I, DePaul University, US
Daniel Nord, Desk Officer, Secretariat of the Weapons of Mass Destruction Commission
Riccardo Olivieri, Technical Officer, World Customs Organization
Louis Réchaussat, Chairman, OECD Task Force on BRCs
Roger Roffey, Research Director, Department of International and Security Affairs, Swedish Ministry of Defence
Christine Rohde, DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Ted Whiteside, Head of the Weapons of Mass Destruction Centre, NATO

Moderated by Giles Merritt, Director, New Defence Agenda
16:00 - 17:30
Protection: Vaccine development and health care training

Vaccinating emergency services, military personnel and, in a wider scenario, civilian populations against bioterrorism agents remain highly controversial. Studies on the prophylactic use of vaccines have so far yielded mixed results, with some indicating a higher mortality rate from the vaccine than from an actual outbreak of disease. Significant divisions exist within the European Union on vaccination policy, vaccine stockpiling and use before and during an event. Should Member States define a single vaccination policy at the European level? Which authorities should distribute vaccinations and should an EU Protocol be developed on "ring" versus mass vaccination during an emergency disease outbreak? Should such a policy be based on the class of disease? What role should NATO play?

Tim Brooks, Director, Public Health Affairs, Porton Down, UK
Jill Dekker-Bellamy, Bio-Defence Consultant and Co-Chair of Session II, New Defence Agenda
Mick Garstang, Director of Marketing, Acambis
Janusz Kocik, Senior Research Associate, Military Institute of Hygiene & Epidemiology, Poland
René Snacken, Director, Head of the Department of Epidemiology-Toxiology, Belgian Scientific Institute of Public Health

Moderated by Giles Merritt, Director, New Defence Agenda